The U.S. home infusion therapy market is projected to witness significant growth during the forthcoming time period owing to the technological advancements, and the rising elderly population. Home infusion is a clinically suitable treatment option for patients with a wide array of acute as well as chronic conditions, which range from bacterial infections to progressively complex conditions like immune deficiencies, bleeding disorders, nutrition support, and late-stage heart failure.

Home infusion is capable of affording the independence of patients and better quality of life since it is offered in the comfort of the patienta??s home effectively fitting the needs of the patient. Additionally, it also gives better outcomes, is considerably cost-effective, and provides enhanced safety.

U.S. home infusion therapy market is segmented in terms of product, application, and regional landscape.

With respect to product, the U.S. home infusion therapy market is classified into intravenous sets, needleless connectors, infusion pumps, and IV cannulas. Among these, the IV Cannulas segment was valued at $574.2 million in 2019 and is expected to grow at a CAGR of 10.2% over the forecast period.

IV or intravenous cannulation is basically a technique where a cannula is put inside a vein to give venous access. The venous access further allows the sampling of the blood and administration of blood products, chemotherapy, medications, fluids, and parenteral nutrition.

Based on application, the U.S. home infusion therapy market is categorized into specialty pharmaceuticals, chemotherapy, parenteral nutrition, enteral nutrition, hydration therapy, anti-infective, and others. Among these, the hydration therapy segment was valued at $170.2 million and is expected to grow at a CAGR of 10.8% over the forecast time period.

Hydration therapy provides several benefits such as reduced recovery time, boosts immunity, it also improves cognitive functions, flushes toxins form the body, is efficient, it tends to improve the joint, skin, and the muscle health.

The chemotherapy application segment was valued at $155.1 million in 2019 and is expected to grow at a CAGR of 10.6% over the projected timeframe. The specialty pharmaceuticals segment was valued at around $1.1 billion in 2019 and is expected to grow at a CAGR of 10.2% over the forecast time frame.

On the geographical front, the East North Central market was valued at $1.2 billion and is projected to grow at a CAGR of 10.2% over the forecast time period. The West South-Central market was valued at $853.0 million and is projected to grow at a CAGR of 5.1% over the projected time period.

The East South-Central market was valued at $468.6 million and is estimated to grow at a CAGR 7.7% over the forecast time period. The Mountain States market was valued at $657.4 million and is estimated to grow at a CAGR 11.5% over the forecast period.